Mesa Laboratories MLAB Biopharmaceutical Development — Cost Of Revenue

Other segment segments

Similar metrics at other companies

VCYTBiopharmaceutical and other revenue — Cost of Revenue

$8K-99.7%

ASHLife Sciences — Cost Of Revenue

$109M-6.8%

FLGTTherapeutic Development — Cost Of Revenue

$8K—

ANABBiopharma Company — Research And Development Expense Excluding Acquired In Process Cost

$34.9M-8.4%

VCYTBiopharmaceutical and other revenue — Other cost

$8K-99.2%

TMOLaboratory Products and Biopharma Services — Cost of revenues

$4.76B+7.9%

Questions, answered.

What is Mesa Laboratories's biopharmaceutical development — cost of revenue?

Mesa Laboratories (MLAB) reported biopharmaceutical development — cost of revenue of $3.65M in Q1 2026.

How has Mesa Laboratories's biopharmaceutical development — cost of revenue changed year-over-year?

Mesa Laboratories's biopharmaceutical development — cost of revenue decreased by 32.0% year-over-year, from $5.37M to $3.65M.

What is the long-term trend for Mesa Laboratories's biopharmaceutical development — cost of revenue?

Over 2 years (2024 to 2026), Mesa Laboratories's biopharmaceutical development — cost of revenue has grown at a 14.5% compound annual growth rate (CAGR), from $15.31M to $20.07M.

What does biopharmaceutical development — cost of revenue mean?

Represents the total direct costs incurred to produce the goods and services sold by the Biopharmaceutical Development segment. This includes materials, labor, and overhead directly associated with the segment's revenue-generating activities. It is a fundamental metric for evaluating the direct operational efficiency and production cost control of the business unit.